The balance between apoB and apoA-I, i.e. the apoB/apoA-I ratio, indicates cardiovascular risk; the higher the ratio, the higher is the risk G. Walldius.

Slides:

Advertisements

Similar presentations

Summary Prepared by Melvyn Rubenfire, MD

Advertisements

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

© Copyright 2009 by the American Association for Clinical Chemistry LOX Index, a Novel Predictive Biochemical Marker for Coronary Heart Disease and Stroke.

Break the Fast: “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control.

Proportion of cases and controls who are obese or overweight S. Yusuf, Lancet 2005; 366:

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Blood samples available from study participants with myocardial infarction and controls by ethnic origin Matthew J McQueen, et al. Lancet 2008; 372:

{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.

Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.

Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

By: David Tran, Mercer University, 2013 Pharm.D. Candidate Prececptor: Dr. Ali Rahimi Morbidity and Mortality Associated with Dyslipidemia.

10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Analyses of Covariance Comparing k means adjusting for 1 or more other variables (covariates) Ho: u 1 = u 2 = u 3 (Adjusting for X) Combines ANOVA and.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.

Metabolic syndrome from a gender and cardiovascular perspective Eva Swahn.

Association of C-Reactive Protein and Acute Myocardial Infarction in HIV-Infected Patients Virginia A. Triant, MD, MPH, James B. Meigs, MD, MPH, and Steven.

INTERHEART: Focus on 9 risk or protective factors

Fibrinogen in South Asians Dr Kirti Kain MD MRCP Academic Unit of Molecular Vascular Medicine Leeds University Leeds United Kingdom.

ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.

Amarenco P, Labreuche J. Lancet Neurol 2009;8:

4S: Scandinavian Simvastatin Survival Study

Parish S, et al. Eur Heart J 2009 [Epub ahead of print]

Probability and odds Suppose we a frequency distribution for the variable “TB status” The probability of an individual having TB is frequencyRelative.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Lipid Profile, Plasma Apolipoproteins, and Risk of.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.

Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Major Lipids, Apolipoproteins, and Risk of Vascular.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nonfasting Glucose, Ischemic Heart Disease, and.

Date of download: 9/19/2016 From: Angiotensinogen Mutations and Risk for Ischemic Heart Disease, Myocardial Infarction, and Ischemic Cerebrovascular Disease:

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?

“The Bulgarians stand at the basis of human civilization

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients.

Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.

AIM HIGH Niacin plus Statin to prevent vascular events

HDL cholesterol and cardiovascular risk Epidemiological evidence

Copyright © 2012 American Medical Association. All rights reserved.

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol by Allan.

HDL cholesterol and cardiovascular risk

Cardiovascular risk factors: are they useful screening tests?

FATS- Familial Atherosclerosis Treatment Study

Progress and Promise in RAAS Blockade

Baseline characteristics of patients

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

K June 03 03/06/20 1.

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

Hazard ratios for the primary end point by subgroup of achieved LDL cholesterol (adjusted for age, sex, baseline calculated LDL cholesterol, diabetes,

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Potential mechanisms whereby statins may reduce the risk of stroke

An example of the Lancet

Baseline Characteristics According to Sex

Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Women’s Health Study: Baseline Characteristics Part 1

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

A patient with inferior acute myocardial infarction with grade II ischaemia. A patient with inferior acute myocardial infarction with grade II ischaemia.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

International Journal of Cardiology

Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.

Presentation transcript:

The balance between apoB and apoA-I, i.e. the apoB/apoA-I ratio, indicates cardiovascular risk; the higher the ratio, the higher is the risk G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

AMORIS: Fatal MI Men, n=1267: adjusted for age, TC, and TG G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

Odds ratio for fatal myocardial infarction in men (hatched line) and women (solid line) in relation to the apolipoprotein B (apoB)/apoA-I ratio expressed in deciles (log-plot) G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

Odds ratio for fatal myocardial infarction in men and women pooled together in relation to the apolipoprotein B (apoB)/apoA-I ratio expressed in deciles (log- plot) G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

The AMORIS study: values for low-density lipoprotein cholesterol (LDL C; x-axis) versus apolipoprotein B (apoB; y-axis) in 50–70-year-old men G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

Different values for LDL C correspond to values for the apoB/apoA-I ratio according to the regression line between LDL C (x-axis) versus the apoB/apoA-I ratio (y-axis) for men and women G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

The AMORIS study: glucose and the apoB)/apoA-I ratio versus relative risk of fatal myocardial infarction (y-axis) in men with elevated glucose values G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

Relative risk of fatal myocardial infarction as a function of increasing glucose values and increasing values of the apoB/apoA-I ratio in men and women G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

The AMORIS study: odds ratio for fatal stroke (all subtypes included) in men and women pooled together in relation to the apoB/apoA-I ratio expressed in deciles (log-plot) G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

The AMORIS study: odds ratio for all events related to atherosclerosis (and ischaemia) in men and women pooled together in relation to the apoB/apoA-I ratio expressed in deciles (log-plot) G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

The INTERHEART study: odds ratio for acute myocardial infarction in men and women pooled together in relation to the apoB/apoA-I ratio expressed in deciles (log-plot) G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

The INTERHEART study: PAR values for the nine risk variables measured in the trial G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

Clinical events and manifestations of atherosclerosis associated with high values of the apoB/apoA-I ratio independent of LDL C values and/or other conventional risk factors G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519

Risk of myocardial infarction in relation to increasing values of the apoB/apoA-I ratio G. Walldius and I. Jungner J. Internal Medicine 2006; 259: 493– 519